Mutations in MGAM have been linked to enhanced response rates, increased PD‐L1 expression, and higher TMB levels in NSCLC patients, suggesting a potential role in modulating tumor‐infiltrating immune cells.54 The gene discussed is MGAM; the disease is neoplasm.